Menu
GeneBe

SMPD1

sphingomyelin phosphodiesterase 1

Basic information

Region (hg38): 11:6390439-6394998

Links

ENSG00000166311NCBI:6609OMIM:607608HGNC:11120Uniprot:P17405AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Niemann-Pick disease (Definitive), mode of inheritance: AR
  • Niemann-Pick disease type A (Definitive), mode of inheritance: AR
  • Niemann-Pick disease type A (Strong), mode of inheritance: AR
  • Niemann-Pick disease type B (Strong), mode of inheritance: AR
  • Niemann-Pick disease type A (Supportive), mode of inheritance: AR
  • Niemann-Pick disease type B (Supportive), mode of inheritance: AR
  • Niemann-Pick disease type B (Strong), mode of inheritance: AR
  • acid sphingomyelinase deficiency (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Niemann-Pick disease, type A; Niemann-Pick disease, type BARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingBiochemical; Cardiovascular; Endocrine; Gastrointestinal; Neurologic; Ophthalmologic; Pulmonary13516139; 2023926; 1301192; 1618760; 8664904; 12369017; 15877209; 16434659; 17360762; 17632693; 18815062; 19050888; 19405096; 20301544; 20386867; 22613662
It has been suggested that it could be useful to screen for NPB in heart disease clinics (for patients with very low HDL), or in endocrinology clinics (in individuals with growth retardation)

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SMPD1 gene.

  • Niemann-Pick disease, type B;Niemann-Pick disease, type A (322 variants)
  • Niemann-Pick disease, type A;Niemann-Pick disease, type B (306 variants)
  • Niemann-Pick disease, type A (297 variants)
  • not provided (216 variants)
  • Sphingomyelin/cholesterol lipidosis (97 variants)
  • not specified (66 variants)
  • Inborn genetic diseases (56 variants)
  • Niemann-Pick disease, type B (46 variants)
  • SMPD1-related condition (7 variants)
  • Niemann-pick disease, intermediate, protracted neurovisceral (2 variants)
  • Abnormality of metabolism/homeostasis (1 variants)
  • Ceroid lipofuscinosis, neuronal, 6A (1 variants)
  • See cases (1 variants)
  • Acid sphingomyelinase deficiency (1 variants)
  • Intellectual disability (1 variants)
  • Gaucher disease (1 variants)
  • Niemann-Pick disease, type C1 (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SMPD1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
6
clinvar
220
clinvar
5
clinvar
233
missense
23
clinvar
92
clinvar
123
clinvar
11
clinvar
3
clinvar
252
nonsense
19
clinvar
21
clinvar
40
start loss
0
frameshift
53
clinvar
56
clinvar
2
clinvar
1
clinvar
112
inframe indel
1
clinvar
2
clinvar
14
clinvar
2
clinvar
7
clinvar
26
splice donor/acceptor (+/-2bp)
2
clinvar
13
clinvar
15
splice region
1
2
10
13
non coding
2
clinvar
8
clinvar
13
clinvar
9
clinvar
32
Total 98 188 153 247 24

Highest pathogenic variant AF is 0.000276

Variants in SMPD1

This is a list of pathogenic ClinVar variants found in the SMPD1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-6390467-G-A Likely benign (Aug 28, 2018)1187574
11-6390554-G-C Niemann-Pick disease, type A Likely benign (Apr 27, 2017)305192
11-6390560-A-T Niemann-Pick disease, type A Uncertain significance (Jan 13, 2018)879528
11-6390587-G-A Uncertain significance (May 25, 2018)193117
11-6390601-GC-G Niemann-Pick disease, type A • Niemann-Pick disease, type B;Niemann-Pick disease, type A Pathogenic (Apr 14, 2023)553962
11-6390604-C-T Niemann-Pick disease, type B;Niemann-Pick disease, type A Likely benign (Jul 30, 2023)2950502
11-6390606-G-A Niemann-Pick disease, type A • Niemann-Pick disease, type B;Niemann-Pick disease, type A • Sphingomyelin/cholesterol lipidosis • SMPD1-related disorder Conflicting classifications of pathogenicity (Jan 31, 2024)281886
11-6390605-C-CGCTTTGTGAT Niemann-Pick disease, type A Likely pathogenic (May 11, 2023)2679041
11-6390607-C-G Niemann-Pick disease, type B;Niemann-Pick disease, type A Likely benign (Oct 07, 2023)2952652
11-6390607-C-T Niemann-Pick disease, type A;Niemann-Pick disease, type B Likely benign (Sep 09, 2020)1138900
11-6390608-T-C Sphingomyelin/cholesterol lipidosis Uncertain significance (Oct 14, 2020)991120
11-6390614-G-GCGTCACTC Niemann-Pick disease, type A Likely pathogenic (May 25, 2023)2679040
11-6390622-C-A Niemann-Pick disease, type B;Niemann-Pick disease, type A Likely benign (Dec 31, 2022)2942842
11-6390624-G-T Sphingomyelin/cholesterol lipidosis Uncertain significance (Apr 14, 2020)991121
11-6390626-C-T Niemann-Pick disease, type A • Niemann-Pick disease, type B;Niemann-Pick disease, type A • SMPD1-related disorder Pathogenic/Likely pathogenic (Nov 02, 2023)550117
11-6390628-G-A Niemann-Pick disease, type A;Niemann-Pick disease, type B Likely benign (Jan 16, 2021)1627584
11-6390631-C-T Niemann-Pick disease, type B;Niemann-Pick disease, type A Likely benign (Jul 16, 2023)2949937
11-6390633-GC-G Niemann-Pick disease, type B;Niemann-Pick disease, type A • Niemann-Pick disease, type A Pathogenic/Likely pathogenic (Apr 11, 2022)1460100
11-6390634-C-T Niemann-Pick disease, type A;Niemann-Pick disease, type B Likely benign (Aug 25, 2020)1095572
11-6390637-C-T Niemann-Pick disease, type B;Niemann-Pick disease, type A Conflicting classifications of pathogenicity (Sep 03, 2023)593157
11-6390640-GT-G Niemann-Pick disease, type A;Niemann-Pick disease, type B Pathogenic (Mar 09, 2022)1386053
11-6390643-C-T Niemann-Pick disease, type B;Niemann-Pick disease, type A Likely benign (Aug 04, 2022)2004815
11-6390647-C-A Niemann-Pick disease, type B;Niemann-Pick disease, type A Likely benign (Aug 04, 2023)2942669
11-6390648-G-A Niemann-Pick disease, type A;Niemann-Pick disease, type B Uncertain significance (Apr 04, 2022)2150799
11-6390650-G-T Niemann-Pick disease, type A • Niemann-Pick disease, type B;Niemann-Pick disease, type A Pathogenic/Likely pathogenic (Jun 29, 2022)552301

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SMPD1protein_codingprotein_codingENST00000342245 64574
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
3.89e-100.5451256730751257480.000298
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.09743823771.010.00002194010
Missense in Polyphen124135.090.917931531
Synonymous-0.9951751591.100.000009201369
Loss of Function1.231824.60.7310.00000129241

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001250.000123
Ashkenazi Jewish0.001390.00139
East Asian0.000.00
Finnish0.00004620.0000462
European (Non-Finnish)0.0003140.000308
Middle Eastern0.000.00
South Asian0.0007190.000719
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Converts sphingomyelin to ceramide (PubMed:1840600, PubMed:18815062, PubMed:27659707, PubMed:25920558). Also has phospholipase C activities toward 1,2-diacylglycerolphosphocholine and 1,2-diacylglycerolphosphoglycerol. {ECO:0000269|PubMed:1840600, ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:27659707, ECO:0000305}.; FUNCTION: Isoform 3 lacks residues that bind the cofactor Zn(2+) and has no enzyme activity. {ECO:0000269|PubMed:1840600, ECO:0000305}.;
Disease
DISEASE: Niemann-Pick disease A (NPDA) [MIM:257200]: An early- onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, mental retardation, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. {ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1391960, ECO:0000269|PubMed:15221801, ECO:0000269|PubMed:15877209, ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:1718266, ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:19405096, ECO:0000269|PubMed:2023926, ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430884, ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:8680412, ECO:0000269|PubMed:8693491, ECO:0000269|PubMed:9266408}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Niemann-Pick disease B (NPDB) [MIM:607616]: A late-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Clinical signs involve only visceral organs. The most constant sign is hepatosplenomegaly which can be associated with pulmonary symptoms. Patients remain free of neurologic manifestations. However, a phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. In Niemann-Pick disease type B, onset of the first symptoms occurs in early childhood and patients can survive into adulthood. {ECO:0000269|PubMed:12369017, ECO:0000269|PubMed:12556236, ECO:0000269|PubMed:1301192, ECO:0000269|PubMed:15241805, ECO:0000269|PubMed:16010684, ECO:0000269|PubMed:1618760, ECO:0000269|PubMed:16472269, ECO:0000269|PubMed:18815062, ECO:0000269|PubMed:1885770, ECO:0000269|PubMed:19050888, ECO:0000269|PubMed:19405096, ECO:0000269|PubMed:20386867, ECO:0000269|PubMed:21621718, ECO:0000269|PubMed:22613662, ECO:0000269|PubMed:22818240, ECO:0000269|PubMed:23252888, ECO:0000269|PubMed:23430512, ECO:0000269|PubMed:25920558, ECO:0000269|PubMed:26084044, ECO:0000269|PubMed:26499107, ECO:0000269|PubMed:27338287, ECO:0000269|PubMed:27659707, ECO:0000269|PubMed:8051942, ECO:0000269|PubMed:8664904}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Lysosome - Homo sapiens (human);Necroptosis - Homo sapiens (human);Sphingolipid signaling pathway - Homo sapiens (human);Sphingolipid metabolism - Homo sapiens (human);Ovarian Infertility Genes;phospholipids as signalling intermediaries;Metabolism of lipids;sphingomyelin metabolism/ceramide salvage;Metabolism;ceramide signaling pathway;Glycosphingolipid metabolism;Glycosphingolipid metabolism;Sphingolipid metabolism;TRAIL signaling pathway;TNF receptor signaling pathway ;IL2 signaling events mediated by PI3K;FAS (CD95) signaling pathway;Ceramide signaling pathway (Consensus)

Recessive Scores

pRec
0.414

Intolerance Scores

loftool
0.0435
rvis_EVS
1.72
rvis_percentile_EVS
96.48

Haploinsufficiency Scores

pHI
0.121
hipred
N
hipred_score
0.396
ghis
0.404

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.947

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Smpd1
Phenotype
hematopoietic system phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); respiratory system phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; cellular phenotype;

Gene ontology

Biological process
sphingomyelin metabolic process;sphingomyelin catabolic process;glycosphingolipid metabolic process;signal transduction;nervous system development;termination of signal transduction;positive regulation of protein dephosphorylation;response to cocaine;positive regulation of apoptotic process;negative regulation of MAP kinase activity;ceramide biosynthetic process
Cellular component
extracellular space;lysosome;endosome;plasma membrane;lamellar body;lysosomal lumen;extracellular exosome
Molecular function
sphingomyelin phosphodiesterase activity;protein binding;phosphoric diester hydrolase activity;zinc ion binding;hydrolase activity, acting on glycosyl bonds;acid sphingomyelin phosphodiesterase activity